Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD

Abstract Background To evaluate changes in central macular thickness (CMT) and visual outcome in patients with neovascular age-related macular degeneration (AMD) treated initially with bevacizumab and subsequently switched to either aflibercept or ranibizumab. Methods Observational clinical study wa...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Maria Waizel, Margarita G. Todorova, Michael Masyk, Katharina Wolf, Annekatrin Rickmann, Khaled Helaiwa, Björn R. Blanke, Peter Szurman
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	BMC 2017-05-01
Schriftenreihe:	BMC Ophthalmology
Schlagworte:	Vascular endothelial growth factor a Ranibizumab Aflibercept Bevacizumab VEGF switch Vascular endothelial growth factor
Online-Zugang:	http://link.springer.com/article/10.1186/s12886-017-0471-x
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!